Research progress of matrix metalloproteinase in pulmonary tuberculosis_West China Medical Journal

Authors：

TAN Ling ¹ , WANG Jingjing ² , MA Xue ³ ,  LEI Fengfeng ^1,4

1. The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P. R. China;
2. The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, Gansu 730000, P. R. China;
3. School of Medicine of Jiangsu University, Zhenjiang, Jiangsu 212000, P. R. China;
4. Department of Respiratory and Critical Care Medicine, Gansu Provincial People’s Hospital, Lanzhou, Gansu 730000, P. R. China;

Corresponding?author：

LEI Fengfeng, Email: leifengfenglf@163.com

Keywords：

Matrix metalloproteinase; pulmonary tuberculosis; regulatory mechanism

DOI：

10.7507/1002-0179.202401245

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Tuberculosis is a chronic infectious diseases caused by Mycobacterium tuberculosis. Its high morbidity and mortality have posed a serious threat to global public health. Matrix metalloproteinase (MMP) is a proteolytic enzyme involved in regulating extracellular matrix degradation and remodeling. MMP is highly expressed in pulmonary tuberculosis, and its expression is regulated by genes, epigenetic modifications, cellular signaling pathways, immune regulation, and cellular environment. MMP is a potential target for the treatment of pulmonary tuberculosis. Therefore, this article summarizes the expression and related mechanisms of MMP in pulmonary tuberculosis, aiming to provide a reference for the diagnosis and treatment of pulmonary tuberculosis.

Citation： TAN Ling, WANG Jingjing, MA Xue, LEI Fengfeng. Research progress of matrix metalloproteinase in pulmonary tuberculosis. West China Medical Journal, 2024, 39(4): 630-634. doi: 10.7507/1002-0179.202401245 Copy

1.	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organisation, 2022.
2.	Kathamuthu GR, Kumar NP, Moideen K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and extra-pulmonary tuberculosis. Front Immunol, 2020, 11: 419.
3.	Kumar NP, Moideen K, Nancy A, et al. Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes among patients with pulmonary tuberculosis. JAMA Netw Open, 2020, 3(12): e2027754.
4.	Walker NF, Karim F, Moosa MYS, et al. Elevated plasma matrix metalloproteinase 8 associates with sputum culture positivity in pulmonary tuberculosis. J Infect Dis, 2022, 226(5): 928-932.
5.	Tiwari D, Martineau AR. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. Semin Immunol, 2023, 65: 101672.
6.	Miow QH, Vallejo AF, Wang Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. J Clin Invest, 2021, 131(15): e141895.
7.	Christopoulou ME, Papakonstantinou E, Stolz D. Matrix metalloproteinases in chronic obstructive pulmonary disease. Int J Mol Sci, 2023, 24(4): 3786.
8.	Duan C, Yu X, Feng X, et al. Expression profiles of matrix metalloproteinases and their inhibitors in nasal polyps. J Inflamm Res, 2024, 17: 29-39.
9.	Li Y, Wang W, Li L, et al. MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm. Life Sci, 2020, 253: 117659.
10.	Mu?oz-Sáez E, Moracho N, Learte AIR, et al. Dynamic expression of membrane type 1-matrix metalloproteinase (Mt1-mmp/Mmp14) in the mouse embryo. Cells, 2021, 10(9): 2448.
11.	Shang W, Wang Y, Liang X, et al. SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression. J Pathol, 2021, 253(2): 148-159.
12.	陸霓虹, 孫婭萍, 金媛, 等. 早期分泌抗原靶6及基質金屬蛋白酶9評估結核性毀損肺嚴重程度的應用價值. 中國防癆雜志, 2021, 43(2): 139-142.
13.	Shanmugasundaram K, Talwar A, Madan K, et al. Pulmonary functions and inflammatory biomarkers in post-pulmonary tuberculosis sequelae. Tuberc Respir Dis (Seoul), 2022, 85(2): 175-184.
14.	Santoso A, Rasiha R, Zainal ATF, et al. Transforming growth factor-β and matrix metalloproteinases as potential biomarkers of fibrotic lesions induced by tuberculosis: a systematic review and meta-analysis. BMJ Open, 2023, 13(10): e070377.
15.	Brilha S, Wysoczanski R, Whittington AM, et al. Monocyte adhesion, migration, and extracellular matrix breakdown are regulated by integrin αVβ3 in Mycobacterium tuberculosis infection. J Immunol, 2017, 199(3): 982-991.
16.	Rohlwink UK, Walker NF, Ordonez AA, et al. Matrix metalloproteinases in pulmonary and central nervous system tuberculosis-a review. Int J Mol Sci, 2019, 20(6): 1350.
17.	Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science, 2010, 327(5964): 466-469.
18.	Song L, Zhang D, Wang H, et al. Automated quantitative assay of fibrosis characteristics in tuberculosis granulomas. Front Microbiol, 2024, 14: 1301141.
19.	Sabir N, Hussain T, Mangi MH, et al. Matrix metalloproteinases: expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif, 2019, 52(4): e12649.
20.	Taylor JL, Hattle JM, Dreitz SA, et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun, 2006, 74(11): 6135-6144.
21.	Subbian S, Tsenova L, O’Brien P, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol, 2011, 179(1): 289-301.
22.	Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One, 2010, 5(8): e12266.
23.	Kübler A, Luna B, Larsson C, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J Pathol, 2015, 235(3): 431-444.
24.	Parasa VR, Muvva JR, Rose JF, et al. Inhibition of tissue matrix metalloproteinases interferes with Mycobacterium tuberculosis-induced granuloma formation and reduces bacterial load in a human lung tissue model. Front Microbiol, 2017, 8: 2370.
25.	Herrera MT, Guzmán-Beltrán S, Bobadilla K, et al. Human pulmonary tuberculosis: understanding the immune response in the bronchoalveolar system. Biomolecules, 2022, 12(8): 1148.
26.	Muefong CN, Owolabi O, Donkor S, et al. Major neutrophil-derived soluble mediators associate with baseline lung pathology and post-treatment recovery in tuberculosis patients. Front Immunol, 2021, 12: 740933.
27.	Albuquerque VVS, Kumar NP, Fukutani KF, et al. Plasma levels of C-reactive protein, matrix metalloproteinase-7 and lipopolysaccharide-binding protein distinguish active pulmonary or extrapulmonary tuberculosis from uninfected controls in children. Cytokine, 2019, 123: 154773.
28.	Sengupta S, Pattanaik KP, Mishra S, et al. Epigenetic orchestration of host immune defences by Mycobacterium tuberculosis. Microbiol Res, 2023, 273: 127400.
29.	劉莉, 馬沁梅, 于嘉霖, 等. 基質金屬蛋白酶對結核肉芽腫形成及免疫調控作用的研究進展. 中國病理生理雜志, 2022, 38(6): 1113-1119.
30.	Amaral EP, Vinhaes CL, Oliveira-de-Souza D, et al. The interplay between systemic inflammation, oxidative stress, and tissue remodeling in tuberculosis. Antioxid Redox Signal, 2021, 34(6): 471-485.
31.	Ong CW, Elkington PT, Friedland JS. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med, 2014, 190(1): 9-18.
32.	Moores RC, Brilha S, Schutgens F, et al. Epigenetic regulation of matrix metalloproteinase-1 and -3 expression in Mycobacterium tuberculosis infection. Front Immunol, 2017, 8: 602.
33.	Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix metalloproteinases in tuberculosis. Eur Respir J, 2011, 38(2): 456-464.
34.	Zhou X, Lie L, Liang Y, et al. GSK-3α/β activity negatively regulates MMP-1/9 expression to suppress Mycobacterium tuberculosis infection. Front Immunol, 2022, 12: 752466.
35.	鄧敏華, 張睢揚, 王英. 結核后肺疾病的研究進展. 中華結核和呼吸雜志, 2022, 45(10): 1041-1045.
36.	Poh XY, Loh FK, Friedland JS, et al. Neutrophil-mediated immunopathology and matrix metalloproteinases in central nervous system - tuberculosis. Front Immunol, 2022, 12: 788976.
37.	Belton M, Brilha S, Manavaki R, et al. Hypoxia and tissue destruction in pulmonary TB. Thorax, 2016, 71(12): 1145-1153.
38.	Whittington AM, Turner FS, Baark F, et al. An acidic microenvironment in tuberculosis increases extracellular matrix degradation by regulating macrophage inflammatory responses. PLoS Pathog, 2023, 19(7): e1011495.
39.	Xu Y, Wang L, Zimmerman MD, et al. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog, 2018, 14(4): e1006974.
40.	Ordonez AA, Pokkali S, Sanchez-Bautista J, et al. Matrix metalloproteinase inhibition in a murine model of cavitary tuberculosis paradoxically worsens pathology. J Infect Dis, 2019, 219(4): 633-636.

1. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organisation, 2022.
2. Kathamuthu GR, Kumar NP, Moideen K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and extra-pulmonary tuberculosis. Front Immunol, 2020, 11: 419.
3. Kumar NP, Moideen K, Nancy A, et al. Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes among patients with pulmonary tuberculosis. JAMA Netw Open, 2020, 3(12): e2027754.
4. Walker NF, Karim F, Moosa MYS, et al. Elevated plasma matrix metalloproteinase 8 associates with sputum culture positivity in pulmonary tuberculosis. J Infect Dis, 2022, 226(5): 928-932.
5. Tiwari D, Martineau AR. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. Semin Immunol, 2023, 65: 101672.
6. Miow QH, Vallejo AF, Wang Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. J Clin Invest, 2021, 131(15): e141895.
7. Christopoulou ME, Papakonstantinou E, Stolz D. Matrix metalloproteinases in chronic obstructive pulmonary disease. Int J Mol Sci, 2023, 24(4): 3786.
8. Duan C, Yu X, Feng X, et al. Expression profiles of matrix metalloproteinases and their inhibitors in nasal polyps. J Inflamm Res, 2024, 17: 29-39.
9. Li Y, Wang W, Li L, et al. MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm. Life Sci, 2020, 253: 117659.
10. Mu?oz-Sáez E, Moracho N, Learte AIR, et al. Dynamic expression of membrane type 1-matrix metalloproteinase (Mt1-mmp/Mmp14) in the mouse embryo. Cells, 2021, 10(9): 2448.
11. Shang W, Wang Y, Liang X, et al. SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression. J Pathol, 2021, 253(2): 148-159.
12. 陸霓虹, 孫婭萍, 金媛, 等. 早期分泌抗原靶6及基質金屬蛋白酶9評估結核性毀損肺嚴重程度的應用價值. 中國防癆雜志, 2021, 43(2): 139-142.
13. Shanmugasundaram K, Talwar A, Madan K, et al. Pulmonary functions and inflammatory biomarkers in post-pulmonary tuberculosis sequelae. Tuberc Respir Dis (Seoul), 2022, 85(2): 175-184.
14. Santoso A, Rasiha R, Zainal ATF, et al. Transforming growth factor-β and matrix metalloproteinases as potential biomarkers of fibrotic lesions induced by tuberculosis: a systematic review and meta-analysis. BMJ Open, 2023, 13(10): e070377.
15. Brilha S, Wysoczanski R, Whittington AM, et al. Monocyte adhesion, migration, and extracellular matrix breakdown are regulated by integrin αVβ3 in Mycobacterium tuberculosis infection. J Immunol, 2017, 199(3): 982-991.
16. Rohlwink UK, Walker NF, Ordonez AA, et al. Matrix metalloproteinases in pulmonary and central nervous system tuberculosis-a review. Int J Mol Sci, 2019, 20(6): 1350.
17. Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science, 2010, 327(5964): 466-469.
18. Song L, Zhang D, Wang H, et al. Automated quantitative assay of fibrosis characteristics in tuberculosis granulomas. Front Microbiol, 2024, 14: 1301141.
19. Sabir N, Hussain T, Mangi MH, et al. Matrix metalloproteinases: expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif, 2019, 52(4): e12649.
20. Taylor JL, Hattle JM, Dreitz SA, et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun, 2006, 74(11): 6135-6144.
21. Subbian S, Tsenova L, O’Brien P, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol, 2011, 179(1): 289-301.
22. Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One, 2010, 5(8): e12266.
23. Kübler A, Luna B, Larsson C, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J Pathol, 2015, 235(3): 431-444.
24. Parasa VR, Muvva JR, Rose JF, et al. Inhibition of tissue matrix metalloproteinases interferes with Mycobacterium tuberculosis-induced granuloma formation and reduces bacterial load in a human lung tissue model. Front Microbiol, 2017, 8: 2370.
25. Herrera MT, Guzmán-Beltrán S, Bobadilla K, et al. Human pulmonary tuberculosis: understanding the immune response in the bronchoalveolar system. Biomolecules, 2022, 12(8): 1148.
26. Muefong CN, Owolabi O, Donkor S, et al. Major neutrophil-derived soluble mediators associate with baseline lung pathology and post-treatment recovery in tuberculosis patients. Front Immunol, 2021, 12: 740933.
27. Albuquerque VVS, Kumar NP, Fukutani KF, et al. Plasma levels of C-reactive protein, matrix metalloproteinase-7 and lipopolysaccharide-binding protein distinguish active pulmonary or extrapulmonary tuberculosis from uninfected controls in children. Cytokine, 2019, 123: 154773.
28. Sengupta S, Pattanaik KP, Mishra S, et al. Epigenetic orchestration of host immune defences by Mycobacterium tuberculosis. Microbiol Res, 2023, 273: 127400.
29. 劉莉, 馬沁梅, 于嘉霖, 等. 基質金屬蛋白酶對結核肉芽腫形成及免疫調控作用的研究進展. 中國病理生理雜志, 2022, 38(6): 1113-1119.
30. Amaral EP, Vinhaes CL, Oliveira-de-Souza D, et al. The interplay between systemic inflammation, oxidative stress, and tissue remodeling in tuberculosis. Antioxid Redox Signal, 2021, 34(6): 471-485.
31. Ong CW, Elkington PT, Friedland JS. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med, 2014, 190(1): 9-18.
32. Moores RC, Brilha S, Schutgens F, et al. Epigenetic regulation of matrix metalloproteinase-1 and -3 expression in Mycobacterium tuberculosis infection. Front Immunol, 2017, 8: 602.
33. Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix metalloproteinases in tuberculosis. Eur Respir J, 2011, 38(2): 456-464.
34. Zhou X, Lie L, Liang Y, et al. GSK-3α/β activity negatively regulates MMP-1/9 expression to suppress Mycobacterium tuberculosis infection. Front Immunol, 2022, 12: 752466.
35. 鄧敏華, 張睢揚, 王英. 結核后肺疾病的研究進展. 中華結核和呼吸雜志, 2022, 45(10): 1041-1045.
36. Poh XY, Loh FK, Friedland JS, et al. Neutrophil-mediated immunopathology and matrix metalloproteinases in central nervous system - tuberculosis. Front Immunol, 2022, 12: 788976.
37. Belton M, Brilha S, Manavaki R, et al. Hypoxia and tissue destruction in pulmonary TB. Thorax, 2016, 71(12): 1145-1153.
38. Whittington AM, Turner FS, Baark F, et al. An acidic microenvironment in tuberculosis increases extracellular matrix degradation by regulating macrophage inflammatory responses. PLoS Pathog, 2023, 19(7): e1011495.
39. Xu Y, Wang L, Zimmerman MD, et al. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog, 2018, 14(4): e1006974.
40. Ordonez AA, Pokkali S, Sanchez-Bautista J, et al. Matrix metalloproteinase inhibition in a murine model of cavitary tuberculosis paradoxically worsens pathology. J Infect Dis, 2019, 219(4): 633-636.

West China Medical Journal

Research progress of matrix metalloproteinase in pulmonary tuberculosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content